Menu Search
Equities

Active Biotech AB publ

BTPC:STU

Active Biotech AB publ

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.045
  • Today's Change0.002 / 4.17%
  • Shares traded0.00
  • 1 Year change-17.90%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Active Biotech AB publ had revenues remain flat at 0.00, though the company grew net income from a loss of 58.37m to a smaller loss of 45.80m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-189.29%
Return on equity-411.16%
Return on investment-322.63%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Active Biotech AB publ fell by 5.58m. Cash Flow from Financing totalled 40.16m or -- of revenues. In addition the company used 45.74m for operations while cash from investing was breakeven.
Cash flow per share-0.1398
Price/Cash flow per share--
Book value per share0.0265
Tangible book value per share0.026
More ▼

Balance sheet in SEKView more

Active Biotech AB publ appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.26% of the market capitalization can be attributed to its 36.22m and debt could be paid in full if management chose.
Current ratio1.72
Quick ratio--
Total debt/total equity0.2396
Total debt/total capital0.1933
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.